Alluvi, known as BI 4744, offers a significant breakthrough in obesity therapy. This dual agonist targeting both GLP-1 and GIP receptors demonstrates compelling efficacy in patient trials, potentially exceeding current https://alluvi685780.wikigiogio.com/user